These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 15785743)

  • 1. Remarks on the BOADICEA model of genetic susceptibility to breast and ovarian cancer.
    van Asperen CJ; Jacobi CE; de Bock GH
    Br J Cancer; 2005 Apr; 92(7):1336-7; author reply 1337-8. PubMed ID: 15785743
    [No Abstract]   [Full Text] [Related]  

  • 2. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic susceptibility to breast and ovarian cancer: risk assessment, genetic counseling, and management issues.
    Shah MR
    Mo Med; 2004; 101(2):105-10; quiz 110-1. PubMed ID: 15119107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cancer incidence in the first-degree relatives of ovarian cancer patients].
    Auranen A; Pukkala E; Mäkinen J; Sankila R; Grénman S; Salmi T
    Duodecim; 1997; 113(1):46-50. PubMed ID: 11370054
    [No Abstract]   [Full Text] [Related]  

  • 5. A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis.
    Shen J; Ambrosone CB; DiCioccio RA; Odunsi K; Lele SB; Zhao H
    Carcinogenesis; 2008 Oct; 29(10):1963-6. PubMed ID: 18660546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
    Kauff ND; Mitra N; Robson ME; Hurley KE; Chuai S; Goldfrank D; Wadsworth E; Lee J; Cigler T; Borgen PI; Norton L; Barakat RR; Offit K
    J Natl Cancer Inst; 2005 Sep; 97(18):1382-4. PubMed ID: 16174860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic risk assessment for breast and ovarian cancer.
    O'Rourke Tiffen J; Pfeifer K; Fishman DA
    Adv Nurse Pract; 2003 Oct; 11(10):40-8. PubMed ID: 14601495
    [No Abstract]   [Full Text] [Related]  

  • 8. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives.
    Egeli U; Cecener G; Tunca B; Tasdelen I
    Cancer Invest; 2006; 24(5):484-91. PubMed ID: 16939956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer risk prediction models: a workshop on development, evaluation, and application.
    Freedman AN; Seminara D; Gail MH; Hartge P; Colditz GA; Ballard-Barbash R; Pfeiffer RM
    J Natl Cancer Inst; 2005 May; 97(10):715-23. PubMed ID: 15900041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility.
    Wolff TA; Wilson JE
    Am Fam Physician; 2006 Nov; 74(10):1759-60. PubMed ID: 17137007
    [No Abstract]   [Full Text] [Related]  

  • 11. Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent.
    Oros KK; Ghadirian P; Maugard CM; Perret C; Paredes Y; Mes-Masson AM; Foulkes WD; Provencher D; Tonin PN
    Clin Genet; 2006 Oct; 70(4):320-9. PubMed ID: 16965326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Inherited breast and ovarian cancers].
    Gerdes AM; Ejlertsen B
    Ugeskr Laeger; 2006 Jun; 168(24):2367-9. PubMed ID: 16822422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer.
    Spannuth WA; Thaker PH; Sood AK
    Am J Obstet Gynecol; 2007 Apr; 196(4):e6-9. PubMed ID: 17403394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer risk assessment and the genetic counseling process: using hereditary breast and ovarian cancer as an example.
    Prucka SK; McIlvried DE; Korf BR
    Med Princ Pract; 2008; 17(3):173-89. PubMed ID: 18408385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Models of genetic susceptibility to breast cancer.
    Antoniou AC; Easton DF
    Oncogene; 2006 Sep; 25(43):5898-905. PubMed ID: 16998504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel and common BRCA1 mutations in familial breast/ovarian cancer patients from Lithuania.
    Janavicius R; Pepalyte I; Kucinskas V
    Breast Cancer Res Treat; 2009 Sep; 117(2):467-9. PubMed ID: 18763032
    [No Abstract]   [Full Text] [Related]  

  • 19. The RAD51 135 G>C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers.
    Jakubowska A; Gronwald J; Menkiszak J; Górski B; Huzarski T; Byrski T; Edler L; Lubiñski J; Scott RJ; Hamann U
    Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):270-5. PubMed ID: 17301259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
    Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
    Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.